Evolution of care for patients with relapsed glioblastoma

References

• Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC. Histopathology, classification, and grading of gliomas. Glia15, 211–221 (1995).
   PubMed Web of Science ®Google Scholar
• Ohgaki H, Dessen P, Jourde B et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res.64, 6892–6899 (2004).
   PubMed Web of Science ®Google Scholar
• Wöhrer A, Waldhör T, Heinzl H et al. The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J. Neurooncol.95, 401–411 (2009).
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol.10, 459–466 (2009).
   PubMed Web of Science ®Google Scholar
• Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol.17, 2572–2578 (1999).
   PubMed Web of Science ®Google Scholar
• van Vulpen M, Kal HB, Taphoorn MJ, El-Sharouni SY. Changes in blood–brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? Oncol. Rep.9, 683–688 (2002).
   PubMed Web of Science ®Google Scholar
• Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int. J. Radiat. Oncol. Biol. Phys.65, 499–508 (2006).
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11, 83–95 (2007).
   PubMed Web of Science ®Google Scholar
• Kamoun WS, Ley CD, Farrar CT et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J. Clin. Oncol.27, 2542–2552 (2009).
   PubMed Web of Science ®Google Scholar
• Clarke JL, Chang S. Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. Curr. Neurol. Neurosci. Rep.9, 241–246 (2009).
   PubMed Web of Science ®Google Scholar
• Grant R, Liang BC, Slattery J, Greenberg HS, Junck L. Chemotherapy response criteria in malignant glioma. Neurology48, 1336–1340 (1997).
   PubMedGoogle Scholar
• Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for Phase II studies of supratentorial malignant glioma. J. Clin. Oncol.8, 1277–1280 (1990).
   PubMed Web of Science ®Google Scholar
• Wen PY, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J. Clin. Oncol.28, 1963–1972 (2010).
   PubMed Web of Science ®Google Scholar
• Ballman KV, Buckner JC, Brown PD et al. The relationship between six-month progression-free survival and 12-month overall survival end points for Phase II trials in patients with glioblastoma multiforme. Neuro. Oncol.9, 29–38 (2007).
   PubMed Web of Science ®Google Scholar
• Lamborn KR, Yung WK, Chang SM et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro. Oncol.10, 162–170 (2008).
   PubMed Web of Science ®Google Scholar
• Nieder C, Astner ST, Mehta MP, Grosu AL, Molls M. Improvement, clinical course, and quality of life after palliative radiotherapy for recurrent glioblastoma. Am. J. Clin. Oncol.31, 300–305 (2008).
   PubMed Web of Science ®Google Scholar
• Dhermain F, de Crevoisier R, Parker F et al. Role of radiotherapy in recurrent gliomas. Bull. Cancer91, 883–889 (2004).
   PubMed Web of Science ®Google Scholar
• Combs SE, Debus J, Schulz-Ertner D. Radiotherapeutic alternatives for previously irradiated recurrent gliomas. BMC Cancer7, 167 (2007).
   PubMed Web of Science ®Google Scholar
• Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J. Clin. Oncol.23, 8863–8869 (2005).
   PubMed Web of Science ®Google Scholar
• Barbagallo GM, Jenkinson MD, Brodbelt AR. ‘Recurrent’ glioblastoma multiforme, when should we reoperate? Br. J. Neurosurg.22, 452–455 (2008).
   PubMed Web of Science ®Google Scholar
• Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-Brain Tumor Treatment Group. Lancet345, 1008–1012 (1995).
   PubMed Web of Science ®Google Scholar
• Kunwar S, Chang S, Westphal M et al. PRECISE Study Group. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro. Oncol.12, 871–881 (2010).
   PubMedGoogle Scholar
• Park JK, Hodges T, Arko L et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J. Clin. Oncol.28, 3838–3843 (2010).
   PubMed Web of Science ®Google Scholar
• DeAngelis LM, Burger PC, Green SB, Cairncross JG. Malignant glioma: who benefits from adjuvant chemotherapy? Ann. Neurol.44, 691–695 (1998).
   PubMed Web of Science ®Google Scholar
• Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer71, 2585–2597 (1993).
   PubMed Web of Science ®Google Scholar
• Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet359, 1011–1018 (2002).
   PubMed Web of Science ®Google Scholar
• Huncharek M, Muscat J. Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients. Anticancer Res.18, 1303–1311 (1998).
   PubMed Web of Science ®Google Scholar
• Yung WK, Albright RE, Olson J et al. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer83, 588–593 (2000).
   PubMed Web of Science ®Google Scholar
• Brada M, Hoang-Xuan K, Rampling R et al. Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol.12, 259–266 (2001).
   PubMed Web of Science ®Google Scholar
• Yung WK, Prados MD, Yaya-Tur R et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Clin. Oncol.17, 2762–2771 (1999).
   Google Scholar
• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352, 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Tosoni A, Franceschi E et al. A Phase II multicentric trial of fotemustine in patients with recurrent/progressive glioblastoma after radiotherapy plus concomitant and/or adjuvant temozolomide: a GICNO (Gruppo Italiano Cooperativo di Neuro-Oncologia) study. J. Clin. Oncol.26, 108 (2008) (Abstract 2079).
   Google Scholar
• Fabrini MG, Silvano G, Lolli I et al. A multi-institutional Phase II study on second-line fotemustine chemotherapy in recurrent glioblastoma. J. Neurooncol.92, 79–86 (2009).
   PubMed Web of Science ®Google Scholar
• Scoccianti S, Detti B, Sardaro A et al. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs19, 613–620 (2008).
   PubMedGoogle Scholar
• Kong DS, Lee DS, Kim HJ et al. Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro. Oncol.12, 289–296 (2010).
   PubMed Web of Science ®Google Scholar
• Berrocal A, Perez Segura P, Gil M et al. Extended-schedule dose-dense temozolomide in refractory gliomas. J. Neurooncol.96, 417–422 (2010).
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol.27, 4733–4740 (2009).
   PubMed Web of Science ®Google Scholar
• Cloughesy T, Vredenburgh JJ, Day B, Das A, Friedman HS. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study J. Clin. Oncol.28, 181s (2010) (Abstract 2008).
   PubMed Web of Science ®Google Scholar
• Rosenthal MA, Ashley DL, Cher L. BCNU as second line therapy for recurrent high-grade glioma previously treated with temozolomide. J. Clin. Neurosci.11, 374–375 (2004).
   Google Scholar
• Batchelor T, Mulholland P, Neyns B et al. A Phase III randomized study comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, with lomustine alone in recurrent gliobastoma patients. Ann. Oncol.21(8), viii1–viii (2010) (Abstract LBA7).
   Google Scholar
• Wong S, Rosenthal MA, Dowling A et al. Phase II study of two-weekly temozolomide in patients with high-grade gliomas. J. Clin. Neurosci.13, 18–22 (2006).
   Google Scholar
• Wick A, Felsberg J, Steinbach JP et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J. Clin. Oncol.25, 3357–3361 (2007).
   PubMed Web of Science ®Google Scholar
• Kim JT, Kim JS, Ko KW et al. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol. Rep.16, 33–39 (2006).
   PubMed Web of Science ®Google Scholar
• Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE. A Phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neuro. Oncol.4, 39–43 (2002).
   PubMed Web of Science ®Google Scholar
• Balmaceda C, Peereboom D, Pannullo S et al. Multi-institutional Phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer112, 1139–1146 (2008).
   Google Scholar
• Brandes AA, Tosoni A, Cavallo G et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: Phase II study from Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br. J. Cancer95, 1155–1160 (2006).
   PubMed Web of Science ®Google Scholar
• Perry JR, Rizek P, Cashman R, Morrison M, Morrison T. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the ‘rescue’ approach. Cancer113, 2152–2157 (2008).
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Gerson SL, Denis L et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br. J. Cancer88, 1004–1011 (2003).
   PubMed Web of Science ®Google Scholar
• Brada M, Stenning S, Gabe R et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J. Clin. Oncol.28, 4601–4608 (2010).
   PubMed Web of Science ®Google Scholar
• Weller M, Tabatabai G, Reifenberger G et al. Dose-intensified rechallenge with temozolomide: one week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma J. Clin. Oncol.28, 20s (2010) (Abstract TPS154).
   Google Scholar
• Wick A, Pascher C, Wick W et al. Rechallenge with temozolomide in patients with recurrent gliomas. J. Neurol.256, 734–741 (2009).
   PubMed Web of Science ®Google Scholar
• Brandes AA, Tosoni A, Basso U et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a Phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J. Clin. Oncol.22, 4779–4786 (2004).
   PubMed Web of Science ®Google Scholar
• Silvani A, Lamperti E, Gaviani P et al. Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. J. Neurooncol.87, 143–151 (2008).
   Google Scholar
• Soffietti R, Costanza A, Laguzzi E, Nobile M, Rudà R. A Phase II study of first-line temozolomide and second-line PCV in recurrent/progressive malignant gliomas. J. Clin. Oncol.22, 125s (2004) (Abstract 1374).
   Google Scholar
• Huang H, Held-Feindt J, Buhl R, Mehdorn HM, Mentlein R. Expression of VEGF and its receptors in different brain tumors. Neurol. Res.27, 371–377 (2005).
   PubMed Web of Science ®Google Scholar
• Chaudhry IH, O’Donovan DG, Brenchley PE, Reid H, Roberts IS. Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology39, 409–415 (2001).
   PubMed Web of Science ®Google Scholar
• Fukumura D, Xu L, Chen Y, Gohongi T, Seed B, Jain RK. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res.61, 6020–6024 (2001).
   PubMed Web of Science ®Google Scholar
• Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro. Oncol.7, 369 (2005) (Abstract 342).
   Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol.25, 4722–4729 (2007).
   PubMed Web of Science ®Google Scholar
• Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology70, 779–787 (2008).
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol.27, 740–745 (2009).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology72, 772–773 (2009).
   Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst.92, 205–216 (2000).
   PubMed Web of Science ®Google Scholar
• Desjardins A, Vredenburgh JJ, Reardon DA et al. Long-term survival from the initial trial of bevacizumab and irinotecan. J. Clin. Oncol.28, 191s (2010) (Abstract 2045).
   Google Scholar
• Hofer S, Elandt K, Greil R et al. Encouraging overall survival (OS) with bevacizumab (Bev) in patients with recurrent high-grade glioma (HGG) treated outside clinical trials. Ann. Oncol.21(8), viii329 (2010) (Abstract 1057P).
   Google Scholar
• Grudé F, Campone M, Soulié P et al. Bevacizumab and irinotecan in recurrent malignant glioma: results of a French retrospective cohort study OMIT of 264 patients in real practice). Ann. Oncol.21(8), viii329 (2010) (Abstract 1058P).
   Google Scholar
• Taillibert S, Hoang-Xunag K, Guiu S et al. Bevacizumab (B) with irinotecan (I) in recurrent glioblastoma (GBM): a national retrospective cohort of the ANOCEF (Association des Neuro-Oncologues d’Expression Française) Group. Ann. Oncol.21(8), viii329 (2010) (Abstract 1056P).
   Google Scholar
• Gil MJ, de las Peñas R, Reynés G et al. Bevacizumab plus irinotecan in recurrent malignant glioma showed high overall survival in a retrospective study. Poster presentation at: The Society for NeuroOncology Scientific Meeting. Montreal, Canada, 18–21 November 2010 (NO-73).
   Google Scholar
• Batchelor TT, Duda DG, di Tomaso E et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol.28, 2817–2823 (2010).
   PubMed Web of Science ®Google Scholar
• Sorensen AG, Batchelor TT, Zhang WT et al. A ‘vascular normalization index’ as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res.69, 5296–5300 (2009).
   PubMed Web of Science ®Google Scholar
• Wen P, Prados MD, Schiff D et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). J. Clin. Oncol.28, 181s (2010) (Abstract 2006).
   PubMed Web of Science ®Google Scholar
• Yamada S, Bu XY, Khankaldyyan V, Gonzales-Gomez I, McComb JG, Laug WE. Effect of the angiogenesis inhibitor cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery59, 1304–1312 (2006).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Fink KL, Mikkelsen T et al. Randomized Phase II study of cilengitide, an integrin-targeting arginine–glycine–aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol.26, 5610–5617 (2008).
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Neyns B et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol.28, 2712–2718 (2010).
   PubMed Web of Science ®Google Scholar
• Graff JR, McNulty AM, Hanna KR et al. The protein kinase Cβ-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res.65, 7462–7469 (2005).
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kotliarova S, Butman JA et al. A Phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro. Oncol.12, 181–189 (2010).
   PubMed Web of Science ®Google Scholar
• Wick W, Puduvalli VK, Chamberlain MC et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol.28, 1168–1174 (2010).
   PubMed Web of Science ®Google Scholar
• Wen PY, Yung WK, Lamborn KR et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99–08. Clin. Cancer Res.12, 4899–4907 (2006).
   PubMed Web of Science ®Google Scholar
• Raymond E, Brandes AA, Dittrich C et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J. Clin. Oncol.26, 4659–4665 (2008).
   PubMed Web of Science ®Google Scholar
• Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann. Oncol.16, 1702–1708 (2005).
   PubMed Web of Science ®Google Scholar
• Reardon DA, Egorin MJ, Quinn JA et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J. Clin. Oncol.23, 9359–9368 (2005).
   PubMed Web of Science ®Google Scholar
• Peters K, Desjardins A, Vredenburgh JJ et al. Imatinib mesylate plus hydroxyurea for adults with recurrent/progressive low-grade glioma: final Phase II study results. J. Clin. Oncol.28, 194s (2010).
   Google Scholar
• Reardon DA, Dresemann G, Taillibert S et al. Multicentre Phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br. J. Cancer101, 1995–2004 (2009).
   PubMed Web of Science ®Google Scholar
• Dresemann G, Weller M, Rosenthal MA et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J. Neurooncol.96, 393–402 (2010).
   PubMed Web of Science ®Google Scholar
• Raizer J, Abrey LE, Lassman AB et al. A Phase II trial of erlotinib in patients with recurrent malignant gliomas and non progressive glioblastoma multiforme postradiation therapy. Neuro. Oncol.12, 95–103 (2010).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Brandes AA, Rampling R et al. Randomized Phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol.27, 1268–1274 (2009).
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Lassman AB, Mischel PS et al. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J. Neurooncol.92, 99–105 (2009).
   Google Scholar
• Haas-Kogan DA, Prados MD, Tihan T et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl Cancer Inst.97, 880–887 (2005).
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med.353, 2012–2024 (2005).
   PubMed Web of Science ®Google Scholar
• Van Meir EG, Hadjipanayis CG, Norden AD et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J. Clin.60, 166–193 (2010).
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Sampson JH. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro. Oncol.13, 3–13 (2011).
   PubMed Web of Science ®Google Scholar
• Wick W, Naumann U, Weller M. Transforming growth factor-β: a molecular target for the future therapy of glioblastoma. Curr. Pharm. Des.12, 341–349 (2006).
   PubMed Web of Science ®Google Scholar
• Bogdahn U, Hau P, Stockhammer G et al. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled Phase IIb study. Neuro. Oncol.13, 132–142 (2011).
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Sampson JH. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin. Biol. Ther.9, 1087–1098 (2009).
   PubMed Web of Science ®Google Scholar